Literature DB >> 14694131

Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics.

Shinji Watanabe1, Tokiko Watanabe, Takeshi Noda, Ayato Takada, Heinz Feldmann, Luke D Jasenosky, Yoshihiro Kawaoka.   

Abstract

We established a plasmid-based system for generating infectious Ebola virus-like particles (VLPs), which contain an Ebola virus-like minigenome consisting of a negative-sense copy of the green fluorescent protein gene. This system produced nearly 10(3) infectious particles per ml of supernatant, equivalent to the titer of Ebola virus generated by a reverse genetics system. Interestingly, infectious Ebola VLPs were generated, even without expression of VP24. Transmission and scanning electron microscopic analyses showed that the morphology of the Ebola VLPs was indistinguishable from that of authentic Ebola virus. Thus, this system allows us to study Ebola virus entry, replication, and assembly without biosafety level 4 containment. Furthermore, it may be useful in vaccine production against this highly pathogenic agent.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14694131      PMCID： PMC368804          DOI： 10.1128/jvi.78.2.999-1005.2004

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  29 in total

1.  Structural characterization and membrane binding properties of the matrix protein VP40 of Ebola virus.

Authors:  R W Ruigrok; G Schoehn; A Dessen; E Forest; V Volchkov; O Dolnik; H D Klenk; W Weissenhorn
Journal:  J Mol Biol       Date:  2000-06-30       Impact factor: 5.469

2.  Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture.

Authors:  Gabriele Neumann; Heinz Feldmann; Shinji Watanabe; Igor Lukashevich; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Ebola virus VP40-induced particle formation and association with the lipid bilayer.

Authors:  L D Jasenosky; G Neumann; I Lukashevich; Y Kawaoka
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.

Authors:  Z Y Yang; H J Duckers; N J Sullivan; A Sanchez; E G Nabel; G J Nabel
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

5.  Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses.

Authors:  S Y Chan; R F Speck; M C Ma; M A Goldsmith
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.

Authors:  P Pushko; J Geisbert; M Parker; P Jahrling; J Smith
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Vesicular release of ebola virus matrix protein VP40.

Authors:  J Timmins; S Scianimanico; G Schoehn; W Weissenhorn
Journal:  Virology       Date:  2001-04-25       Impact factor: 3.616

8.  Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins.

Authors:  J A Wilson; M Bray; R Bakken; M K Hart
Journal:  Virology       Date:  2001-08-01       Impact factor: 3.616

9.  Mutational analysis of the putative fusion domain of Ebola virus glycoprotein.

Authors:  H Ito; S Watanabe; A Sanchez; M A Whitt; Y Kawaoka
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

10.  Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems.

Authors:  E Mühlberger; M Weik; V E Volchkov; H D Klenk; S Becker
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103
View more
  64 in total

1.  Minigenome-based reporter system suitable for high-throughput screening of compounds able to inhibit Ebolavirus replication and/or transcription.

Authors:  Luke D Jasenosky; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

2.  Oligomerization of Ebola virus VP40 is essential for particle morphogenesis and regulation of viral transcription.

Authors:  T Hoenen; N Biedenkopf; F Zielecki; S Jung; A Groseth; H Feldmann; S Becker
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

3.  Dual selection mechanisms drive efficient single-gene reverse genetics for rotavirus.

Authors:  Shane D Trask; Zenobia F Taraporewala; Karl W Boehme; Terence S Dermody; John T Patton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

4.  VP24 of Marburg virus influences formation of infectious particles.

Authors:  Sandra Bamberg; Larissa Kolesnikova; Peggy Möller; Hans-Dieter Klenk; Stephan Becker
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Functional mapping of the nucleoprotein of Ebola virus.

Authors:  Shinji Watanabe; Takeshi Noda; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

6.  Ebola virus VP35-VP40 interaction is sufficient for packaging 3E-5E minigenome RNA into virus-like particles.

Authors:  Reed F Johnson; Sarah E McCarthy; Peter J Godlewski; Ronald N Harty
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

7.  Crystal structure of the C-terminal domain of Ebola virus VP30 reveals a role in transcription and nucleocapsid association.

Authors:  Bettina Hartlieb; Tadeusz Muziol; Winfried Weissenhorn; Stephan Becker
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-03       Impact factor: 11.205

8.  Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.

Authors:  Masahiro Kajihara; Andrea Marzi; Eri Nakayama; Takeshi Noda; Makoto Kuroda; Rashid Manzoor; Keita Matsuno; Heinz Feldmann; Reiko Yoshida; Yoshihiro Kawaoka; Ayato Takada
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

9.  Identification of functional domains in reovirus replication proteins muNS and mu2.

Authors:  Takeshi Kobayashi; Laura S Ooms; James D Chappell; Terence S Dermody
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

10.  The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals.

Authors:  Martina Trunschke; Dominik Conrad; Sven Enterlein; Judith Olejnik; Kristina Brauburger; Elke Mühlberger
Journal:  Virology       Date:  2013-04-11       Impact factor: 3.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.